PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19841739-0	2009	Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).	Imatinib Mesylate	0-8	ATP binding cassette subfamily C member 10	Homo sapiens	109-113	
24103790-5	2014	In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR.	Imatinib Mesylate	94-102	ATP binding cassette subfamily C member 10	Homo sapiens	17-23	
24103790-5	2014	In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR.	Imatinib Mesylate	94-102	ATP binding cassette subfamily C member 10	Homo sapiens	163-169	
19841739-0	2009	Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).	Imatinib Mesylate	0-8	ATP binding cassette subfamily C member 10	Homo sapiens	115-121	
19841739-4	2009	In this study, we examined the effects of BCR-Abl tyrosine kinase inhibitors imatinib, nilotinib and dasatinib on the activity and expression of MRP7 in HEK293 cells transfected with MRP7, designated HEK-MRP7-2.	Imatinib Mesylate	77-85	ATP binding cassette subfamily C member 10	Homo sapiens	145-149	
19841739-5	2009	METHODOLOGY AND/OR PRINCIPAL FINDINGS: We report for the first time that imatinib and nilotinib reversed MRP7-mediated multidrug resistance.	Imatinib Mesylate	73-81	ATP binding cassette subfamily C member 10	Homo sapiens	105-109	
19841739-7	2009	In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine.	Imatinib Mesylate	13-21	ATP binding cassette subfamily C member 10	Homo sapiens	108-112	
19841739-7	2009	In addition, imatinib and nilotinib (1-5 microM) produced a significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-MRP7-2 cells to paclitaxel and vincristine.	Imatinib Mesylate	13-21	ATP binding cassette subfamily C member 10	Homo sapiens	179-183	
19841739-8	2009	Imatinib and nilotinib, at 5 microM, significantly increased the accumulation of [(3)H]-paclitaxel in HEK-MRP7-2 cells.	Imatinib Mesylate	0-8	ATP binding cassette subfamily C member 10	Homo sapiens	106-110	
19841739-9	2009	The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 microM) also significantly inhibited the efflux of paclitaxel.	Imatinib Mesylate	44-52	ATP binding cassette subfamily C member 10	Homo sapiens	26-30	
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Imatinib Mesylate	13-21	ATP binding cassette subfamily C member 10	Homo sapiens	44-48	
19841739-10	2009	CONCLUSIONS: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the efflux of paclitaxel via MRP7.	Imatinib Mesylate	13-21	ATP binding cassette subfamily C member 10	Homo sapiens	149-153